Delhi High Court Declares “CALPOL” a Well-Known Trademark in Pharmaceutical Sector: GSK v. Walter Healthcare

Summary 

In GlaxoSmithKline Pharmaceuticals Ltd. v. Walter Healthcare Pvt. Ltd. & Anr. [CS(COMM) 403/2025], the Delhi High Court declared the trademark “CALPOL” a well-known trademark under the Trade Marks Act, 1999. While the underlying trademark infringement dispute concerning the mark “WALPOL” was amicably settled between the parties, the Court proceeded to examine whether CALPOL satisfied the statutory criteria for recognition as a well-known mark. After considering extensive evidence of long-standing use, substantial sales, widespread promotion, and successful enforcement actions, the Court concluded that CALPOL enjoys immense goodwill and recognition among consumers across India and merits enhanced protection.  

Facts of the Case 

The plaintiff, GlaxoSmithKline Pharmaceuticals Limited (GSK), is one of India’s leading pharmaceutical companies and a part of the global GSK group. The plaintiff has been using the trademark CALPOL since 1991 in relation to pharmaceutical preparations, including tablets, syrups, and oral drops used for the treatment of fever, pain, and common cold symptoms. Over the years, CALPOL has become one of the most recognized medicinal brands in India and is sold through an extensive network of distributors, stockists, pharmacies, and online platforms.  

The dispute arose when the plaintiff discovered that the defendants were using and seeking registration of the mark “WALPOL” for pharmaceutical products. GSK contended that WALPOL was deceptively similar to CALPOL, differing only in the first letter while retaining the same suffix and overall structure. Given the identical nature of the goods and overlapping consumer base, the plaintiff argued that the impugned mark was likely to cause confusion among consumers. A suit for trademark infringement and passing off was therefore instituted before the Delhi High Court.  

During the pendency of the proceedings, the parties arrived at a settlement. The defendants agreed to discontinue use of the mark WALPOL, withdraw their trademark application, and pay damages of ₹2 lakh to the plaintiff. The only surviving issue before the Court was the plaintiff’s request for declaration of CALPOL as a well-known trademark.  

Issue before the Court

Whether the trademark CALPOL satisfied the requirements under Sections 11(6) and 11(7) of the Trade Marks Act, 1999 and was entitled to recognition as a well-known trademark in India.  

Findings of the Court

The Court examined the evidence placed on record in light of the statutory factors governing determination of well-known trademarks. It noted that CALPOL had been continuously, extensively, and uninterruptedly used in India for over three decades and had acquired significant recognition among consumers and healthcare professionals. The plaintiff demonstrated extensive sales figures, with revenues exceeding ₹300 crore in 2024 alone and more than 20 crore units sold. The Court also took note of the substantial expenditure incurred towards advertising and promotion over several years.  

The Court further observed that CALPOL had received extensive coverage in newspapers, business publications, pharmacy journals, and online media. The Court also noted evidence demonstrating the strong association of the mark with the plaintiff’s products in the public domain, including online search results and media references. Additionally, the plaintiff had consistently protected its trademark rights through enforcement actions against infringers and had secured multiple injunctions and decrees in its favour.  

Considering the duration of use, geographical reach, promotional efforts, market presence, and successful enforcement history, the Court found that CALPOL had acquired a formidable reputation and distinctiveness in the pharmaceutical industry.  

Held

The Delhi High Court held that CALPOL satisfied all the criteria prescribed under Sections 11(6) and 11(7) of the Trade Marks Act, 1999. Accordingly, the Court declared CALPOL a well-known trademark within the meaning of Section 2(1)(zg) of the Act and granted the relief sought by the plaintiff.  

Conclusion

This judgment reinforces the importance of long-standing use, consumer recognition, extensive promotion, and vigilant enforcement in securing well-known trademark status. The decision significantly strengthens CALPOL’s protection against dilution, unfair advantage, and unauthorized adoption, including in circumstances extending beyond identical goods and services. It also serves as a reminder that pharmaceutical trademarks, owing to their direct impact on public health, are afforded a high degree of judicial protection, particularly where substantial goodwill and reputation have been establishedover decades of use. 

Last Updated on 13 June, 2026